VRTX vs CRSP
VRTX and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $130.42B | $5.01B |
| P/E (TTM) | 30.0 | — |
| P/B | 6.44 | — |
| P/S | 10.9x | 1427.0x |
| Revenue | $12.59B(TTM) | — |
| Revenue growth (YoY) | 8.9% | -90.6% |
| Net income | $4.41B(TTM) | — |
| Earnings growth (YoY) | 838.1% | -58.8% |
| EPS, diluted | $17.17(TTM) | — |
| EBIT margin | 34.8% | -18933.6% |
| ROE | 19.5% | -33.3% |
| ROIC | 25.0% | -32.6% |
| 1y total return | +31.0% | -10.5% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: VRTX vs CRSP
| Metric | VRTX | CRSP |
|---|---|---|
| End value | $62.9K | $36.8K |
| Total return | +528.9% | +267.9% |
| CAGR | +20.4% | +14.1% |
| Volatility | 32.7% | 64.0% |
| Sharpe | 0.61 | 0.46 |
| Sortino | 0.90 | 0.71 |
| Max drawdown | -41.6% | -85.1% |
Based on 2489 common trading days, 2016-10-19 → 2026-09-15 · risk-free 4.11% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)